UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Journal of clinical oncology, 2017-10, Vol.35 (29), p.3279-3289

2017

Link zum Volltext

Verfügbarkeit prüfen

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Journal of clinical oncology, 2016-05, Vol.34 (13), p.1544-1557

2016

Link zum Volltext

Verfügbarkeit prüfen

Emesis as a predictor of bacteremia in immunocompromised children with central venous catheters and fever

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20566-20566

Richardson, M.

2008

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1046-1046

2020

Link zum Volltext

Verfügbarkeit prüfen

Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1038-1038

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15125-e15125

2020

Link zum Volltext

Verfügbarkeit prüfen

Olaparib-induced severe folate deficiency in women with relapsed ovarian cancer: First report and case series

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e17540-e17540

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence and characteristics of cancer-associated thrombosis in a racially diverse population: A population-based study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13088-e13088

2019

Link zum Volltext

Verfügbarkeit prüfen

Health economic analysis of doublet chemotherapy with and without bevacizumab for first-line treatment of RAS mutant metastatic colorectal cancer based on real-world data

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16048-e16048

2020

Link zum Volltext

Verfügbarkeit prüfen

TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.507-507

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1004-1004

2019

Link zum Volltext

Verfügbarkeit prüfen

FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.TPS42-TPS42

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.6517-6517

2013

Link zum Volltext

Verfügbarkeit prüfen

Meeting requirements for survivorship visits: Interventions for patient identification

Journal of clinical oncology, 2018-03, Vol.36 (7_suppl), p.59-59

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3072-3072

2019

Link zum Volltext

Verfügbarkeit prüfen

Circulating PD-L1 (programmed death-ligand 1) and outcomes in a HER2-positive metastatic breast cancer cohort treated with first-line trastuzumab

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1024-1024

2017

Link zum Volltext

Verfügbarkeit prüfen

An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8002-8002

2017

Link zum Volltext

Verfügbarkeit prüfen

Extracellular matrix (ECM) protein fragments in serum and outcomes in two metastatic breast cancer cohorts

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1085-1085

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.785-785

2017

Link zum Volltext

Verfügbarkeit prüfen

Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.10051-10051

2017

Link zum Volltext

Verfügbarkeit prüfen

Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5042-5042

2017

Link zum Volltext

Verfügbarkeit prüfen

The impact of physician use of electronic medical records on colorectal cancer screening

Journal of clinical oncology, 2014-10, Vol.32 (30_suppl), p.288-288

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5503-5503

2015

Link zum Volltext

Verfügbarkeit prüfen

Resection of colorectal cancer (CRC) metastases in routine practice

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.599-599

2014

Link zum Volltext

Verfügbarkeit prüfen

PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics, onco-phenotype, and molecular analysis

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1510-1510

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(106)

Sprache

Englisch
(106)
Japanisch
(2)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Emesis as a predictor of bacteremia in immunocompromised children with central venous catheters and fever

A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC)

Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors

Olaparib-induced severe folate deficiency in women with relapsed ovarian cancer: First report and case series

Incidence and characteristics of cancer-associated thrombosis in a racially diverse population: A population-based study

Health economic analysis of doublet chemotherapy with and without bevacizumab for first-line treatment of RAS mutant metastatic colorectal cancer based on real-world data

TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC)

FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors

Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer

Meeting requirements for survivorship visits: Interventions for patient identification

Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years

Circulating PD-L1 (programmed death-ligand 1) and outcomes in a HER2-positive metastatic breast cancer cohort treated with first-line trastuzumab

An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma

Extracellular matrix (ECM) protein fragments in serum and outcomes in two metastatic breast cancer cohorts

Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer

Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial

Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

The impact of physician use of electronic medical records on colorectal cancer screening

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study

Resection of colorectal cancer (CRC) metastases in routine practice

PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics, onco-phenotype, and molecular analysis

Aktive Filter

Suchergebnisse filtern